CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
Joan Bladé(Hospital Clínic de Barcelona), David H. Vesole(Hackensack University Medical Center), Sergio Giralt(Memorial Sloan Kettering Cancer Center), Jane F. Apperley(Hammersmith Hospital), Diana Samson(Myeloma UK), Gösta Gahrton, B. Björkstrand, SUNDARr Jagannath, Donna Reece(University Health Network), Morie A. Gertz(Medical University of South Carolina)
Cited by 1,525
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k